Explore the Agenda
8:45 am Morning Refreshments & Check In
Workshop A
9:30 am Accelerating the Next Wave of GLP-1 Therapies by Integrating MIDD & Adaptive Experimental Design for De-Risking Combinations
This intensive workshop will delve into the advanced quantitative strategies necessary for navigating the complexity and high investment of developing multi-target and combination GLP-1 therapeutics. Leveraging deep experience from both large pharma and pioneering biotech, the session will focus on transforming traditional trial execution into a continuous, model-informed decision engine to minimize risk, maximize capital efficiency, and accelerate time to market for novel cardiometabolic solutions.
This workshop will gather experts to discuss:
- Integrating model-informed drug development (MIDD) strategies to reduce the required size and duration of costly Phase 2 and 3 combination trials, ensuring dose selection is robust and scientifically grounded
- Applying advanced pharmacometric (PMX) and PBPK modeling to predict synergistic or antagonistic effects of novel GLP-1 combinations (including oral formulations) and optimize dosing schedules before committing to large-scale clinical studies
- Designing efficient, adaptive clinical protocols that incorporate Bayesian and other quantitative methods to dynamically adjust dose levels, target populations, and hypothesis testing in real-time
- Quantifying the translational power of combination therapies by linking pre-clinical data (neurobiology, whole animal response) directly to human efficacy and safety endpoints to justify increased development spend
- Establishing effective cross-functional decision-making gates between Quantitative Pharmacology, Clinical Development, and Research to accelerate development timelines for therapeutics targeting obesity and MASH/NASH
12:30 pm Lunch Break & Networking
Workshop B
1:30 pm Mapping the Future of GLP-1 Opportunities Onto Bankable Biotech Business Plans to Predict the Billion-Dollar Pivot
This highly interactive and extended workshop offers a deep dive into the GLP-1 landscape, moving beyond clinical data to focus squarely on market opportunity, investor perception, and financial strategy. Attendees will gain practical insights on the most promising “Future of GLP-1” opportunities – from multi-agonists to neurobiology and novel indications – and learn how to translate these scientific concepts into compelling, fundable, and profitable business plans that capture commercial interest. The session integrates real-time audience surveys, displaying live results to benchmark audience sentiment against expert opinion, ensuring maximum engagement and direct relevance.
This workshop will gather experts to discuss:
- Evaluating the true peak sales potential and valuation drivers for next-generation GLP- 1s, including the financial impact of expanding into key indications like MASH, CKD and beyond to neurological disorders and addiction
- Utilizing interactive audience polls to assess which next-frontier innovations (e.g., muscle preservation, oral formulation, neurobiology) investors are actively prioritizing for the next five years
- Analyzing recent M&A and licensing activity in the cardiometabolic space to project which asset types and company profiles are most likely to be acquisition targets and the specific metrics currently driving those deals
- Demonstrating how companies can weave complex GLP-1 mechanisms into an attractive and robust business plan that secures executive and investor buy-in
- Tailoring funding roadmaps and communication strategies to attract different pools of capital (Venture vs. Public Equity) while navigating the stringent non-clinical criteria of investor due diligence